A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
This Phase 3 pivotal efficacy trial will examine the effects of HLD200 (methylphenidate) in
patients aged 6-12 years with ADHD in a naturalistic setting. Following a screening/washout
period (Visit 1), subjects will randomized to double-blind placebo or HLD200 for a period of
3 weeks (Visits 2-5) before assessing clinical study endpoints at last study visit.